|
FDA Wants Comments on Program for Longer New Drug Reviews
The FDA is seeking drugmaker comment on an upcoming independent assessment of its new lengthened review program under the newly reauthorized Prescription Drug User Fee Act (PDUFA).
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives